NCT00189345|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
44
1 country
1
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
October 2005
Date type not reportedThis date has not been verified as actual or estimated.
Patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. Many patients respond to additional cytotoxic treatment with partial or complete responses, yet approximately 100% of these patients will ultimately progress. Novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option.EpCAM is expressed in a large number of epithelial ovarian cancer, fallopian tube or peritoneal cancer tissues. Thus targeting these cancers with an anti-EpCAM antibody is a promising innovative therapeutic approach.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 12, 2005
Actual (reported)September 19, 2005
Actual (reported)October 2005
Date type not reportedThis date has not been verified as actual or estimated.
Selection of better dose level based on the confirmed tumor response.
Evaluation of safety and tolerability
Effects of removab(TM)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Dept. of Gynecology, University of Marburg
Marburg, 35037, Germany
Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Luck HJ, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol. 2011 Oct;123(1):27-32. doi: 10.1016/j.ygyno.2011.06.004. Epub 2011 Jul 5.
Uwe Wagner, Prof.Dr.
AGO Study Group
First Submitted
September 12, 2005
First Posted
September 19, 2005
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
October 2005
Date type not reportedContact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
November 8, 2006
Record last verified: 2003-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: